News
More than half of biotech and pharma job seekers have been looking for their next opportunity for six months or longer, and more than a quarter have searched for over a year, according to a BioSpace LinkedIn poll. Job seekers share their frustrations.
FEATURED STORIES
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
THE LATEST
Vaccinations will be required by January 4 under the new White House plan.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
Both Moderna and Pfizer reported third-quarter financials this week, and it was instantly obvious that the COVID-19 vaccines are huge profit drivers for the companies.
The proceeds will be used to advance the development of their ePLC platform, treatment for chronic Hepatitis B, and a novel class of anti-cancer therapies.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The job cuts, which affect a variety of functions and levels, are expected to slow its cash burn rate and leave the company with sufficient funds on hand to operate until mid-2023.
For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.
Conducting some research before your job interview can help ease your mind. You will feel less stressed once you know what to look forward to during the meeting and which skills will allow you to shine.
This agreement would cap out-of-pocket costs for insulin at $35 a month and all out-of-pocket medical costs for seniors at $2,000 a year.
While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.